These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 31362850)

  • 41. Mechanisms of PARP inhibitor sensitivity and resistance.
    D'Andrea AD
    DNA Repair (Amst); 2018 Nov; 71():172-176. PubMed ID: 30177437
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cellular functions of BRCA genes - from basic science to therapeutics].
    Miki Y
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):498-501. PubMed ID: 22504671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
    Helleday T
    Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    Chen T; Yu T; Zhuang S; Geng Y; Xue J; Wang J; Ai L; Chen B; Zhao Z; Li Y; Wang J; Liang H; Xu Y; Gu Y
    Br J Cancer; 2022 Sep; 127(5):916-926. PubMed ID: 35618786
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
    Guo E; Ishii Y; Mueller J; Srivatsan A; Gahman T; Putnam CD; Wang JYJ; Kolodner RD
    Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19415-19424. PubMed ID: 32719125
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy.
    Ali U; Vungarala S; Tiriveedhi V
    Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397152
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
    De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI
    Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
    Ashworth A
    J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacologic Induction of BRCAness in
    Abbotts R; Dellomo AJ; Rassool FV
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
    Pothuri B
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC
    Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
    Mengwasser KE; Adeyemi RO; Leng Y; Choi MY; Clairmont C; D'Andrea AD; Elledge SJ
    Mol Cell; 2019 Mar; 73(5):885-899.e6. PubMed ID: 30686591
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Kub5-Hera
    Motea EA; Fattah FJ; Xiao L; Girard L; Rommel A; Morales JC; Patidar P; Zhou Y; Porter A; Xie Y; Minna JD; Boothman DA
    Clin Cancer Res; 2018 Dec; 24(24):6459-6470. PubMed ID: 30108102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.
    Bhin J; Paes Dias M; Gogola E; Rolfs F; Piersma SR; de Bruijn R; de Ruiter JR; van den Broek B; Duarte AA; Sol W; van der Heijden I; Andronikou C; Kaiponen TS; Bakker L; Lieftink C; Morris B; Beijersbergen RL; van de Ven M; Jimenez CR; Wessels LFA; Rottenberg S; Jonkers J
    Cell Rep; 2023 May; 42(5):112538. PubMed ID: 37209095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
    Lupo B; Trusolino L
    Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.